Jazz Pharmaceuticals announced a $1.1 billion private offering of 1.875% exchangeable senior notes due in 2032, upsized from an initial $1 billion. The notes, issued by its subsidiary Jazz Investments I Limited, will pay semiannual interest and are exchangeable for Jazz ordinary shares at a premium. The offering is expected to close on August 31, 2026, with net proceeds intended for general corporate purposes. Concurrently, Jazz will repurchase $225 million of its shares, potentially impacting the share price and exchange rate of the notes.
Best Buy reported a strong fiscal Q2 2027 with revenue up 3.6% to $9.78 billion and comparable sales rising 4.1%, surpassing expectations. Adjusted diluted EPS increased 15% to $1.47, helped partly by $34 million in tariff refunds. Following these re...
BP, a major global energy company, is actively managing its portfolio by potentially selling oil and gas assets in Egypt to Energean and investing in new projects like a Halliburton contract in Brazil's offshore field. This strategic move aims to enh...
Cardano's constitutional committee must ratify a governance action by September 6, 2026, to renew four of its seven seats. If not ratified by then, the committee falls below its minimum size of five members, causing a governance standstill where no m...
Bitcoin mining currently consumes 30% of Paraguay's energy, mainly from hydroelectric sources, raising concerns about a potential energy crisis by 2029 if demand continues to grow. Analysts warn that stagnant power generation and a $15 billion invest...
Pernod Ricard reported Q4 2026 earnings per share of $0.42 and revenue of $4.90 billion, both surpassing analyst expectations. However, the company faces significant organic sales declines of 14% in the US and 19% in China due to weak consumer demand...
